Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Detection and cultivation of circulating tumor cells in malignant pleural mesothelioma.

Bobek V, Kacprzak G, Rzechonek A, Kolostova K.

Anticancer Res. 2014 May;34(5):2565-9.

PMID:
24778078
2.

Circulating tumor cells (CTCs) in malignant pleural mesothelioma (MPM).

Yoneda K, Tanaka F, Kondo N, Hashimoto M, Takuwa T, Matsumoto S, Okumura Y, Tsubota N, Sato A, Tsujimura T, Kuribayashi K, Fukuoka K, Tabata C, Nakano T, Hasegawa S.

Ann Surg Oncol. 2014 Dec;21 Suppl 4:S472-80. doi: 10.1245/s10434-013-3399-2.

PMID:
24306661
3.

Circulating tumor cells in pancreatic cancer patients: enrichment and cultivation.

Bobek V, Gurlich R, Eliasova P, Kolostova K.

World J Gastroenterol. 2014 Dec 7;20(45):17163-70. doi: 10.3748/wjg.v20.i45.17163.

4.

In vitro culturing of viable circulating tumor cells of urinary bladder cancer.

Cegan M, Kolostova K, Matkowski R, Broul M, Schraml J, Fiutowski M, Bobek V.

Int J Clin Exp Pathol. 2014 Sep 15;7(10):7164-71.

5.

Circulating tumor cells in localized prostate cancer: isolation, cultivation in vitro and relationship to T-stage and Gleason score.

Kolostova K, Broul M, Schraml J, Cegan M, Matkowski R, Fiutowski M, Bobek V.

Anticancer Res. 2014 Jul;34(7):3641-6.

PMID:
24982381
6.

Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma.

Raphael J, Massard C, Gong IY, Farace F, Margery J, Billiot F, Hollebecque A, Besse B, Soria JC, Planchard D.

Cancer Biomark. 2015;15(2):151-6. doi: 10.3233/CBM-140448.

PMID:
25519011
7.

Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma.

Tabata C, Shibata E, Tabata R, Kanemura S, Mikami K, Nogi Y, Masachika E, Nishizaki T, Nakano T.

BMC Cancer. 2013 Apr 24;13:205. doi: 10.1186/1471-2407-13-205.

8.

Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma.

Burt BM, Rodig SJ, Tilleman TR, Elbardissi AW, Bueno R, Sugarbaker DJ.

Cancer. 2011 Nov 15;117(22):5234-44. doi: 10.1002/cncr.26143.

9.

Increased frequency of circulating invariant natural killer T cells in malignant pleural mesothelioma patients.

Altomare E, Fallarini S, Biaggi G, Gattoni E, Botta M, Lombardi G.

Cancer Biol Ther. 2012 Jul;13(9):702-11.

PMID:
22684580
10.

Circulating levels of transforming growth factor-βeta (TGF-β) and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of distant seeding of circulating tumor cells in patients with metastatic breast cancer.

Divella R, Daniele A, Savino E, Palma F, Bellizzi A, Giotta F, Simone G, Lioce M, Quaranta M, Paradiso A, Mazzocca A.

Anticancer Res. 2013 Apr;33(4):1491-7.

PMID:
23564790
11.

Circulating endothelial cell (CEC) as a diagnostic and prognostic marker in malignant pleural mesothelioma (MPM).

Yoneda K, Tanaka F, Kondo N, Orui H, Hashimoto M, Takuwa T, Matsumoto S, Okumura Y, Tsubota N, Sato A, Tsujimura T, Kuribayashi K, Fukuoka K, Nakano T, Hasegawa S.

Ann Surg Oncol. 2012 Dec;19(13):4229-37. doi: 10.1245/s10434-012-2506-0.

PMID:
22825770
12.

Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.

Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J.

Ann Thorac Surg. 2008 Jan;85(1):265-72; discussion 272.

PMID:
18154821
13.

Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology.

Wendel M, Bazhenova L, Boshuizen R, Kolatkar A, Honnatti M, Cho EH, Marrinucci D, Sandhu A, Perricone A, Thistlethwaite P, Bethel K, Nieva J, Heuvel Mv, Kuhn P.

Phys Biol. 2012 Feb;9(1):016005. doi: 10.1088/1478-3967/9/1/016005.

14.

Is serum thioredoxin-1 a useful clinical marker for malignant pleural mesothelioma?

Maeda R, Tabata C, Tabata R, Eguchi R, Fujimori Y, Nakano T.

Antioxid Redox Signal. 2011 Aug 1;15(3):685-9. doi: 10.1089/ars.2011.3978.

PMID:
21375472
15.

Prognostic factors affecting survival in malignant pleural mesothelioma: analysis of 125 subjects.

Komurcuoglu B, Cirak AK, Kirakli SC, Polat G, Yucel N, Usluer O, Erer O, Balci G, Gayaf M, Guldaval F, Aktogu S, Guclu S, Ozsoz A, Halilcolar H.

Tumori. 2014 Jan-Feb;100(1):55-9. doi: 10.1700/1430.15816.

PMID:
24675492
16.

Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma.

Yao ZH, Tian GY, Yang SX, Wan YY, Kang YM, Liu QH, Yao F, Lin DJ.

Tumour Biol. 2014 Jul;35(7):6839-45. doi: 10.1007/s13277-014-1938-5.

PMID:
25051913
17.

Fibrinolytic system in plasma and pleural fluid in malignant pleural mesothelioma.

Ozdemir O, Emri S, Karakoca Y, Sayinalp N, Akay H, Dündar S, Bariş I.

Thromb Res. 1996 Oct 15;84(2):121-8.

PMID:
8897701
18.

Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer.

Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, Ward T, Blackhall FH, Dive C.

J Clin Oncol. 2012 Feb 10;30(5):525-32. doi: 10.1200/JCO.2010.33.3716.

PMID:
22253462
19.

Highly sensitive enumeration of circulating tumor cells in lung cancer patients using a size-based filtration microfluidic chip.

Huang T, Jia CP, Jun-Yang, Sun WJ, Wang WT, Zhang HL, Cong H, Jing FX, Mao HJ, Jin QH, Zhang Z, Chen YJ, Li G, Mao GX, Zhao JL.

Biosens Bioelectron. 2014 Jan 15;51:213-8. doi: 10.1016/j.bios.2013.07.044.

PMID:
23962709
20.

Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers.

Hiraiwa K, Takeuchi H, Hasegawa H, Saikawa Y, Suda K, Ando T, Kumagai K, Irino T, Yoshikawa T, Matsuda S, Kitajima M, Kitagawa Y.

Ann Surg Oncol. 2008 Nov;15(11):3092-100. doi: 10.1245/s10434-008-0122-9.

PMID:
18766405
Items per page

Supplemental Content

Support Center